Results 211 to 220 of about 16,534,485 (359)
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
Correction: Facilitating research participation through a research navigator programme: researchers' insights from a project with asylum seekers and refugees. [PDF]
A HM, M T, H E, M M.
europepmc +1 more source
Materials Data on Si6Sb2H36(C4O)3 by Materials Project
None Available
openalex +2 more sources
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Machine learning approach for prediction of TBM performance and risk of jamming in Himalayan geology using a cross-project tunnelling database. [PDF]
Katuwal TB, Panthi KK, Basnet CB.
europepmc +1 more source
Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken +7 more
wiley +1 more source
LIMB Demonstration Project Extension. Quarterly report no. 3, November, December 1987--January 1988
Babcock and Wilcox Co., Barberton, OH (United States)
openalex +2 more sources

